TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03295188

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Plasmalogen
Description: Treatment group takes two 0.5 mg plasmalogen capsules per day for 12 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Group takes two placebo capsules per day for 12 weeks.
Study: NCT02370706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: JAK1/JAK2 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: JAK1/JAK2 inhibitor
Study: NCT04492176

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CO2 fractional laser（ACUPULSE,Lumenis）
Description: gradually withdrawn from inside to outside of vaginal. with Acupulse Femtouch mode therapy ( hexagonal spot , 10-12.5m J/cm2 , density 5-15%) ,once a month for a total of 3 times
Study: NCT03376789

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MYL-1501D product using manufacture process V
Description: MYL-1501D product using manufacture process V
Study: NCT04323852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Participants undergoing coronary artery bypass graft (CABG) surgery are randomly allocated to group A (intervention), who receive 3 doses of vitamin D (50000 U) a day for 3 days before surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03953300

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Benralizumab
Description: Benralizumab: 30 mg/mL solution for injection in accessorized prefilled syringe (APFS) will be administered subcutaneously (SC) every 4 weeks for the first 3 doses - Weeks 0, 4 and 8, and then every 8 weeks - Weeks 16, 24, 32, 40.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be administered subcutaneously with accessorized prefilled syringe (APFS) every 4 weeks for the first 3 doses - Weeks 0, 4 and 8, and then every 8 weeks - Weeks 16, 24, 32, 40.
Study: NCT02499874

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz
Description: oral Efavirenz 400mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tenofovir /emtricitabine
Description: tenofovir 245 mg/emtricitabine 200mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tenofovir/lamivudine
Description: tenofovir 245mg/lamivudine 300mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lamivudine/zidovudine
Description: lamivudine 300mg/zidovudine 600mg
Study: NCT00487162

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intensive glycemic control
Description: intravenous insulin titrated every 30 minutes to serum glycemic level of 80-100mg/dl

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: conventional glycemic control
Description: Novo regular insulin administered when glucose level exceeded 200 mg/dl and titrated to maintain level between 180-200 mg/dl
Study: NCT03376789

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MYL-1501D product using manufacture process VI
Description: MYL-1501D product using manufacture process VI
Study: NCT01050933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 250 ppm carbon monoxide
Description: 250 ppm of inhaled carbon monoxide over one hour
Study: NCT01888172

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight Watchers Online Program
Description: Access to the Weight Watchers Online program available via the Internet on personal computers, tablet computers, and smartphones.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight Watchers Online Program
Description: Access to the Weight Watchers Online program available via the Internet on personal computers, tablet computers, and smartphones.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Philips ActiveLink
Description: Provision of a key-chain sized physical activity monitor that interfaces with the Weight Watchers website to promote exercise and give feedback on progress towards exercise goals.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Eating and Activity Newsletter
Description: General information on healthy eating and physical activity habits and the medical consequences of overweight/obesity and weight loss.
Study: NCT01182051

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT or relaxation training
Description: 8 weeks of CBT or relaxation training.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT or relaxation training
Description: 8 weeks of CBT or relaxation training.
Study: NCT03859479

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cold snare polypectomy
Description: After a target polyp was identified, it should be placed at the comfortable position. Then the snare will be opened and encircled the polyp without air aspiration. Then, the snare will be captured the polyp with at least 1-2 mm of surrounding normal tissue. The polyp will be guillotined and would not be lifted or tented until complete closure is achieved. After resection, the mucosal defect the marginal mucosa was carefully observed, with used of magnification and image enhancement. If residual polyp tissue was recognised, additional removal using the cold snare technique or biopsy forceps will be performed. If a submucosal injection prior to snaring was necessary it will be permitted. After polypectomy all patients will be observed for 3-4 days in-hospital

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hot snare polypectomy
Description: After a target polyp was identified, it should be placed at the comfortable position. Then the polyp with minimal normal tissue will be captured by the snare. The ensnared polyp should be tented away from the colonic wall and removed by one the types of electric currents. After resection, the mucosal defect will be washed thoroughly and the marginal mucosa was carefully observed, with used of magnification and image enhancement, such as near focus imaging or narrow band imaging. If a submucosal injection prior to snaring was necessary it would be permitted. If residual polyp tissue was recognised, additional removal using coagulation or biopsy forceps will be performed. After polypectomy all patients will be observed for 3-4 days in-hospital
Study: NCT00562172

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine
Description: Once daily in the morning

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride
Description: Once daily in the morning

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: At least 1000 mg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: At least 1000 mg/day
Study: NCT01487122

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Continuous microwave
Description: Continuous microwave through a great circular electrode, 15 cm from the neck, 20 minutes, 80 watts, 15 sessions in 3 weeks

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Pulsed microwaves
Description: Pulsed microwaves through a great circular electrode, 15 cm away from the neck, 20 minutes, 80 watts, 15 sessions in 3 weeks

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham microwaves
Description: Unplugged microwave generator, great circular electrode, 15 cm away from the neck, 20 minutes, 15 sessions in 3 weeks
Study: NCT00928291

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: procalcitonin
Description: plasma PCT measurement

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: procalcitonin
Description: plasma PCT measurement

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: antibiotic therapy
Description: antibiotic therapy use

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: antibiotic therapy
Description: antibiotic therapy use
Study: NCT04384003

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Shear Wave Ultrasound Elastography
Description: Scanned protocols of sonographic imaging will be used in this study to measure extrinsic (FDL, FHL and PER) and intrinsic (AbdH, FDB and FHB) muscle CSA and thickness, and plantar fascia thickness (at heel, mid and forefoot sites).~The muscle stiffness will be calculated from the program provided by the US machine as shown real time elastography (RTE, unit: KPa).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Shear Wave Ultrasound Elastography
Description: Scanned protocols of sonographic imaging will be used in this study to measure extrinsic (FDL, FHL and PER) and intrinsic (AbdH, FDB and FHB) muscle CSA and thickness, and plantar fascia thickness (at heel, mid and forefoot sites).~The muscle stiffness will be calculated from the program provided by the US machine as shown real time elastography (RTE, unit: KPa).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Shear Wave Ultrasound Elastography
Description: Scanned protocols of sonographic imaging will be used in this study to measure extrinsic (FDL, FHL and PER) and intrinsic (AbdH, FDB and FHB) muscle CSA and thickness, and plantar fascia thickness (at heel, mid and forefoot sites).~The muscle stiffness will be calculated from the program provided by the US machine as shown real time elastography (RTE, unit: KPa).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Shear Wave Ultrasound Elastography
Description: Scanned protocols of sonographic imaging will be used in this study to measure extrinsic (FDL, FHL and PER) and intrinsic (AbdH, FDB and FHB) muscle CSA and thickness, and plantar fascia thickness (at heel, mid and forefoot sites).~The muscle stiffness will be calculated from the program provided by the US machine as shown real time elastography (RTE, unit: KPa).
Study: NCT01204775

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin IR
Description: Tablets, Oral, 500 mg, Once Daily, 17-52 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Metformin)
Description: Tablets, Oral, Once daily, 1-16 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin (Active Rescue)
Description: Tablets, Oral, 500 mg, Titrated as needed, 2-52 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin (Active Rescue)
Description: Tablets, Oral, 500 mg, Titrated as needed, 2-52 weeks
Study: NCT01668992

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family intervention
Description: 12-week parenting skills program for Burmese migrant and displaced children and families.
Study: NCT00276016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: phenylephrine
Description: immediate-release 12 mg capsules for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: phenylephrine
Description: immediate-release 12 mg capsules for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: phenylephrine
Description: immediate-release 12 mg capsules for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: phenylephrine
Description: immediate-release 12 mg capsules for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: phenylephrine
Description: immediate-release 12 mg capsules for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: phenylephrine
Description: immediate-release 12 mg capsules for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pseudoephedrine
Description: 60 mg immediate-release tablets for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pseudoephedrine
Description: 60 mg immediate-release tablets for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pseudoephedrine
Description: 60 mg immediate-release tablets for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pseudoephedrine
Description: 60 mg immediate-release tablets for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pseudoephedrine
Description: 60 mg immediate-release tablets for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pseudoephedrine
Description: 60 mg immediate-release tablets for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo capsules
Study: NCT02854774

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Muscle activation exercises
Description: Activation of either muscles activating the knee or hip.
Study: NCT00276016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo capsules
Study: NCT04384003

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: The 3-D Motion Analysis
Description: The 3-D Motion Analysis, Forceplates and EMG acquisition system and full body kinematic model (Bonita, VICON Corp, UK) in the Biomechanics and Motor Control Laboratory (BMCL).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: The 3-D Motion Analysis
Description: The 3-D Motion Analysis, Forceplates and EMG acquisition system and full body kinematic model (Bonita, VICON Corp, UK) in the Biomechanics and Motor Control Laboratory (BMCL).
Study: NCT04384003

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: The 3-D Motion Analysis
Description: The 3-D Motion Analysis, Forceplates and EMG acquisition system and full body kinematic model (Bonita, VICON Corp, UK) in the Biomechanics and Motor Control Laboratory (BMCL).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: The 3-D Motion Analysis
Description: The 3-D Motion Analysis, Forceplates and EMG acquisition system and full body kinematic model (Bonita, VICON Corp, UK) in the Biomechanics and Motor Control Laboratory (BMCL).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electromyographic
Description: Electromyographic activity (EMG) of AbdH, TA, PL, SO, gluteus medius (Glut Med) and gluteus maximus (Glut Max) will be recorded bilaterally using pairs of surface electrodes. Motor coordination of these muscles will be evaluated through assessment of temporal and spatial parameters of EMG during functional tasks such as kicking in one leg standing. The primary outcome measure will be percentage of EMG relative to maximal voluntary contraction (MVC) on the same side. In order to remove the potential for investigator bias, all data will be presented individually without identification of the muscle, order of trials or whether the trials precede or follow the intervention.
Study: NCT04545541

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebulised unfractionated heparin (UFH)
Description: Nebulised UFH (25,000 Units in 5 mL) will be administered 6-hourly via an Aerogen Solo vibrating mesh nebuliser while patients receive invasive mechanical ventilation in ICU and for a maximum of 10 days.
Study: NCT03435874

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAd63 RH5
Description: Vaccine
Study: NCT03435874

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAd63 RH5
Description: Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAd63 RH5
Description: Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAd63 RH5
Description: Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAd63 RH5
Description: Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA RH5
Description: Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA RH5
Description: Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA RH5
Description: Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA RH5
Description: Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA RH5
Description: Vaccine

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Rabies Vaccine
Description: Vaccine

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Rabies Vaccine
Description: Vaccine

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Rabies Vaccine
Description: Vaccine

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Rabies Vaccine
Description: Vaccine

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Rabies Vaccine
Description: Vaccine
Study: NCT02345148

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: Esketamine 84 mg will be self-administered by participants as intranasal spray at 0, 5 and 10 minutes on Day 1.
Study: NCT01822639

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2944404 FDC
Description: Uncoated, round, yellow white bilayer fixed dose combination tablet containing 5 mg amlodipine and 20 mg enalapril for single dose oral administration in each period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2944404 FDC
Description: Uncoated, round, yellow white bilayer fixed dose combination tablet containing 5 mg amlodipine and 20 mg enalapril for single dose oral administration in each period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg
Description: Emerald-shaped white 5 mg amlodipine table for single dose oral co-administration with enalapril maleate tablet in each period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg
Description: Emerald-shaped white 5 mg amlodipine table for single dose oral co-administration with enalapril maleate tablet in each period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enalapril Maleate 20 mg
Description: Peach triangle shaped 20 mg enalapril maleate tablet for single dose oral co-administration with amlodipine in each period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enalapril Maleate 20 mg
Description: Peach triangle shaped 20 mg enalapril maleate tablet for single dose oral co-administration with amlodipine in each period.
Study: NCT01686464

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone and valacyclovir treatments
Description: patients were administered prednisone as a single dose of 40 mg daily for 5 days; the dose will then be reduced by 10 mg per 5 day, with a total treatment time of 20 days.while taking valacyclovir 400 mg in three doses daily for 10 days.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic and Oxygen Treatment
Description: MOMC treatment was given as daily 20 min section for 10 days with 2\~3 days of intermission between. Oxygen therapy was given simultaneously at a flow rate of 2\~3.0 L / min for the same duration during all acupuncture sections.
Study: NCT03778892

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 'Project Raincoat' Mobile Phone Application
Description: Mobile phone application with weekly input channels for PrEP use, condom use, number of sex partners and sex acts and a calculation of self-HIV risk feedback scoring. Scoring system for attendance of visits, normal blood tests and use of application. Points redeemable for cash. Optional alarm system to remind to take medications and attend visits.
Study: NCT03561714

Intervention type: BEHAVIORAL
Intervention: Cardometabolic Team Intervention
Description: The CMC-TI team included a registered nurse/certified diabetes educator (RN/CDE) Care Manager, medical assistant (MA) Health Coach, and RN Depression Care Manager. Decision support tools guided therapy for glucose, BP, low-density lipoprotein cholesterol (LDL-c), and depression. At the intervention clinic, the 12-month CMC-TI was delivered to all qualifying patients; surveys were administered to evaluate relevant patient-reported outcomes over 12 months.
Study: NCT03063060

Intervention type: OTHER
Intervention: vitamin D levels and Calcium levels examination
Description: observational
Study: NCT03779230

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L19TNF
Description: Patients will be assigned to the following increasing dose levels of L19TNF: 10 and 13 μg/kg.
Study: NCT04408729

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PrEP My Way
Description: Intervention components may be modified pending the input from Aim 1. As currently planned, the peer delivering the PrEP My Way kit will be trained to provide basic education and support use of the kit components. The peer will also have a smart phone to show an instructional video. Participants will communicate with peers via mobile phones (e.g., SMS, WhatsApp) to arrange for kit delivery at Months 1, 3, and 6 via unmarked vehicles at home or a preferred safe site during reasonable hours. Two-way mobile phone communication will also be used to convey test results and provide on-going support and empowerment. Follow-up with the clinic will occur at Month 6 and as needed (e.g., treatment for positive tests).~This intervention aims to increase adherence/persistence on PrEP. We hypothesize that removing the structural barriers and stigma associated with going to the clinic, women may be more likely to continue on PrEP.
Study: NCT00656825

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: P144 cream
Description: P144 cream will be given at a dose of 100 μg/mL

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: P144 cream
Description: P144 cream will be given at a dose of 200 μg/mL

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: P144 cream
Description: P144 cream will be given at a dose of 300 μg/mL

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be randomly given to 4 subjects in each panel
Study: NCT02734966

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Isoglycyrrhizinate Injection 100mg OD
Description: Magnesium Isoglycyrrhizinate Injection 100mg OD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Isoglycyrrhizinate Injection 200mg OD
Description: Magnesium Isoglycyrrhizinate Injection 200mg OD for 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiopronin Injection
Description: Tiopronin Injection 200mg OD